These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37084337)

  • 1. Biosynthesis and Engineered Overproduction of Everninomicins with Promising Activity against Multidrug-Resistant Bacteria.
    Zhu M; Wang L; Zhang H; Zhang L; Tan B; Huang Q; Zhu Y; Zhang C
    ACS Synth Biol; 2023 May; 12(5):1520-1532. PubMed ID: 37084337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-lysine potentiates aminoglycosides against
    Deng W; Fu T; Zhang Z; Jiang X; Xie J; Sun H; Hu P; Ren H; Zhou P; Liu Q; Long Q
    Emerg Microbes Infect; 2020; 9(1):639-650. PubMed ID: 32192413
    [No Abstract]   [Full Text] [Related]  

  • 3. Emergence of Aminoglycoside Resistance Due to armA methylase in Multi-drug Resistant Acinetobacter Baumannii Isolates in a University Hospital in Nepal.
    Shrestha S; Tada T; Shrestha B; Kirikae T; Ohara H; Rijal BP; Pokhrel BM; Sherchand JB
    J Nepal Health Res Counc; 2016 May; 14(33):72-76. PubMed ID: 27885285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everninomicin, a new oligosaccharide antibiotic: its antimicrobial activity, post-antibiotic effect and synergistic bactericidal activity.
    Nakashio S; Iwasawa H; Dun FY; Kanemitsu K; Shimada J
    Drugs Exp Clin Res; 1995; 21(1):7-16. PubMed ID: 7796712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methyltransferase Contingencies in the Pathway of Everninomicin D Antibiotics and Analogues.
    Limbrick EM; Yñigez-Gutierrez AE; Dulin CC; Derewacz DK; Spraggins JM; McCulloch KM; Iverson TM; Bachmann BO
    Chembiochem; 2020 Dec; 21(23):3349-3358. PubMed ID: 32686210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in-vitro activity of SCH 27899, a novel everninomicin, and vancomycin.
    Urban C; Mariano N; Mosinka-Snipas K; Wadee C; Chahrour T; Rahal JJ
    J Antimicrob Chemother; 1996 Feb; 37(2):361-4. PubMed ID: 8707748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
    Leuthner KD; Cheung CM; Rybak MJ
    J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp.
    Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2149-52. PubMed ID: 15155214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heat shock potentiates aminoglycosides against gram-negative bacteria by enhancing antibiotic uptake, protein aggregation, and ROS.
    Lv B; Huang X; Lijia C; Ma Y; Bian M; Li Z; Duan J; Zhou F; Yang B; Qie X; Song Y; Wood TK; Fu X
    Proc Natl Acad Sci U S A; 2023 Mar; 120(12):e2217254120. PubMed ID: 36917671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stalobacin: Discovery of Novel Lipopeptide Antibiotics with Potent Antibacterial Activity against Multidrug-Resistant Bacteria.
    Matsui K; Kan Y; Kikuchi J; Matsushima K; Takemura M; Maki H; Kozono I; Ueda T; Minagawa K
    J Med Chem; 2020 Jun; 63(11):6090-6095. PubMed ID: 32378891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
    Kanj SS; Whitelaw A; Dowzicky MJ
    Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spectrum of gram-positive bacteraemia and in vitro activities of daptomycin, linezolid and vancomycin against organisms isolated from cancer patients.
    Rolston KV; Kapadia M; Tarrand J; Coyle E; Prince RA
    Int J Antimicrob Agents; 2013 Jun; 41(6):516-20. PubMed ID: 23481658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
    Barber KE; Smith JR; Raut A; Rybak MJ
    J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of linezolid and daptomycin against methicillin-resistant coagulase-negative staphylococci with increased MIC for vancomycin isolated from blood cultures in pediatric patients.
    Castagnola E; Amoroso L; Banov L; Faraci M; Loy A; Moscatelli A; Risso F; Barabino P; Ciucci A; Bandettini R
    J Chemother; 2014 Oct; 26(5):273-5. PubMed ID: 24070064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
    Smith PF; Booker BM; Ogundele AB; Kelchin P
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii.
    Juhas M; Widlake E; Teo J; Huseby DL; Tyrrell JM; Polikanov YS; Ercan O; Petersson A; Cao S; Aboklaish AF; Rominski A; Crich D; Böttger EC; Walsh TR; Hughes D; Hobbie SN
    J Antimicrob Chemother; 2019 Apr; 74(4):944-952. PubMed ID: 30629184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
    Laohavaleeson S; Kuti JL; Nicolau DP
    Expert Opin Investig Drugs; 2007 Mar; 16(3):347-57. PubMed ID: 17302529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility of Gram-negative and Gram-positive bacteria collected from Eastern Europe: Results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2011-2016.
    Dowzicky MJ; Chmelařová E
    J Glob Antimicrob Resist; 2019 Jun; 17():44-52. PubMed ID: 30445209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model.
    LaPlante KL; Rybak MJ; Leuthner KD; Chin JN
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1298-303. PubMed ID: 16569844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of linezolid and other antibiotics against Gram-positive bacteria from the major teaching hospitals in Kuwait.
    Al Sweih N; Mokaddas E; Jamal W; Phillips OA; Rotimi VO
    J Chemother; 2005 Dec; 17(6):607-13. PubMed ID: 16433190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.